Navigation Links
Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
Date:5/22/2008

SAN CARLOS, Calif., May 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that Bharatt Chowrira, Ph.D., J.D. has joined the Company as Chief Operating Officer and Head of the PEGylation Business Unit. His responsibilities include overseeing and managing all aspects of the PEGylation Business Unit, including research and manufacturing, as well as operations across the Company. He will also serve as Chairman of Nektar India Pvt., Ltd. He will report to Nektar President and CEO Howard W. Robin.

"Bharatt has a rare combination of expertise in molecular biology, business strategy, and intellectual property -- and a proven track record of building shareholder value," said Nektar President and CEO Howard W. Robin. "He will be hugely important to our efforts to develop a robust therapeutic pipeline by leveraging and expanding our industry leading PEGylation technology platform."

Dr. Chowrira had previously served as Executive Director, Worldwide Licensing & External Research at Merck & Co. in San Francisco. He was responsible for identifying and evaluating R&D, licensing and partnering opportunities across all therapeutics areas, therapeutic modalities (including small molecules, biologics, vaccines and oligonucleotides), and technology platforms, throughout Asia. Dr. Chowrira was a key member of the team that established collaboration agreements between Merck and leading pharmaceutical firms in India such as Nicholas Piramal and Ranbaxy Labs. Dr. Chowrira also served as Vice President of Sirna Therapeutics, a wholly owned subsidiary of Merck, where his responsibilities included strategic planning and licensing.

Prior to Merck, Dr. Chowrira was a member of the executive management team at Sirna T
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
2. Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
3. Basil Zimmo Joins Finesse Solutions as Vice-President of Software
4. Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing
5. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
6. Harvey Morgan Joins CryoLife Board of Directors
7. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
8. Dr. Arie S. Belldegrun, MD, FACS Joins Two River Group Holdings as Chairman and Partner
9. Robert W. Lee, Ph.D. Joins Particle Sciences as Vice President of Pharmaceutical Development
10. Dr. Elizabeth Brown Joins Argenta TEC
11. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Whitehouse Laboratories is ... the Parenteral Drug Association (PDA) to host ... on container closure integrity testing. This lecture/laboratory course will ... and philosophies detailed in the recently proposed revision to ... The course will span container closure integrity testing (leak ...
(Date:9/29/2014)... 30, 2014 Each year in ... require medical attention. In the military, burn injury ... to battlefield medical care. More than 800 service ... Burn wounds heal slowly, remain inflamed and often ... physically debilitating and functionally damaging. While developments in ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of the ... of cartilage repair, regeneration, allograft reconstruction and research ... the world gathered to discuss the future of ... of Regenerative Medicine symposium, Cartilage Regeneration: State ... included Orthopedic Biosurgery, Minced Juvenile Allograft, and State ...
(Date:9/29/2014)... emerging diseases and biodiversity loss requires evolutionary thinking, ... Science Express that was co-authored by Bruce ... Agriculture and Life Sciences. , For the first ... reviewed progress in addressing a broad set of ... approaches that consider evolutionary histories and the likelihood ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Faster Healing with Fewer Scars 2World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3
... Kansas to its annual promotional campaign of biotechnological, pharmaceutical and medical device companies ... , , (Logo:   ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the ...
... July 29 Omeros Corporation (Nasdaq: OMER ) ... facility under which it may sell up to $40 ... Opportunity, Ltd. (the "investor") over a 24-month period. Omeros is ... enter into and consummate other equity, debt and non-dilutive financing ...
... ,, LONDON , ... pleased,to announce the appointment of Dr Neill Moray Mackenzie ... to CMPT a long record of executive,board level management ... Genetics Ltd, Oxford Biomedica plc (an LSE,listed company), Avidex ...
Cached Biology Technology:BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Omeros Secures $40 Million Committed Equity Financing Facility 2Omeros Secures $40 Million Committed Equity Financing Facility 3Omeros Secures $40 Million Committed Equity Financing Facility 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 2CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 5
(Date:9/30/2014)... Munich report that a new class of chemical ... drugs. They have also pinpointed the relevant target ... agents. , Researchers led by LMU,s Professor ... Technische Universitt Mnchen have identified a class of ... the fight against malignant tumors. The compound is ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may cause ... in mBio , the online open-access journal of the ... the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed ... gained weight when fed a high-fat diet. Mice that ... even when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the American Association of Immunologists 2013 ... from July 13-18, 2013. These awards are meant ... scientists from underrepresented groups into the mainstream of ...
... progress in the search for the first broad-spectrum drugs ... common infectious diseases. Their study on these potential drugs ... the journal ACS Medicinal Chemistry Letters . ... HRV infections cause mild disease, they can lead to ...
... teachers to sing melodies accurately, according to a new ... the University of Kaiserslautern in Germany. Their analysis of ... songbirds, brain processes. The work is published online in ... is considered to be one of the most complex ...
Cached Biology News:Songbirds turn on and tune up 2
Recombinant Feline IFN-alpha...
Anti-OSMR Monoclonal Antibody Research Focus: cytokine/growth factor Storage: 4C Shipping Temperature: 4C...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Biology Products: